Harvard Bio's Q4 Revenues Rise 22 Percent as R&D Swells and Losses Narrow | GenomeWeb
NEW YORK (GenomeWeb News) — Harvard Bioscience yesterday said fourth-quarter revenue rose 22 percent as R&D spending increased 17 percent, and losses narrowed by 75 percent.
Total receipts for the three months ended Dec. 30, 2006, increased to $21.7 million from $17.8 million year over year.
 
The company said revenue grew “across various product lines,” but was mainly due to greater demand for physiology and cell-biology equipment, “particularly in Asia Pacific and in Europe.”
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.